T2ND34 trade ideas
$TNDM Tandem Diabetes On Breakout watchAlert set for break above $93.00,
Indicators bullish.
$100 first target as key psychological resistance .
$105 second target with confluence of
Fibonacci expansion and extension level.
Strong historical weekly resistance level also.
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.
TNDM getting ready for another leg upTNDM is poised here to break up. Can see it flagging here, but I'd really only trade this once it creates a new local high, and love to really see a daily close up there (~92). A nice bounce off the daily yellow 21 ema, and then a close above the daily purple 10 ema. RSI crossing above the ema, stochs bouncing off the neutral zone and holding in bullish control. I've been long since 72, but there is another nice entry coming up. If I was more aggressive, I might take it on the breakout from the flag, but I think caution in this volatile market is prudent. Target is ~115, which is the 382 from ultimate high to low. Also the edge of the next big volume block. For the 92 trade, I'll be using this local low of ~80 as the stop (could change if we continue to flag out more and set in a bit of lower local low).
TNDM Bull Flag Double BottomTNDM formed a double bottom within a bull flag. Looking for continuation of trend up.
$TNDM can rise in the next daysContextual immersion trading strategy idea.
Tandem Diabetes Care is a medical device company, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States.
I am looking for good earnings on 30 Apr.
The demand for shares of the company looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $75,48;
stop-loss — $72,25.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Trade Journal: Long $TNDM - 4/16/2020TNDM has been on my watchlist for a long trade and today the trade triggered. Ever since bouncing from 44 lows to 70 TNDM has been consolidating sideways and formed a solid Ascending Triangle pattern. This pattern is also right under the 50DMA making this a potentially powerful breakout. I also like the fact TNDM is holding above the rising 5DMA.
Entry - 70.86
Stop Loss - 68.60
Target - 80
Tandem Diabetes Corp Bullish $tndm
Possible entry $81.50
Target price $95
Short interest 7.64%
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Trade Journal: Long TNDM - 2/3/2020TNDM has been on my watchlist for a very long time and recently, TNDM broke out of it's nearly 1 year parallel channel. The volume at the breakout was significant, and TNDM has the potential to run 20+ points due to the significance of the breakout pattern. What caught my eye is the multiple Inside Day Candlestick that were printed yesterday and today right above the breakout point. TNDM has the potential to blast off either tomorrow or the next day.
Entry - 75.94
Stop Loss - 73.20
Target - 90.00
Tandem Diabetes Care bottom end of 2019 followed by 7-10% bounceHi all, TNDM has some great news that is reflected in the stock concerning automated insulin pumps for diabetics recently approved by the FDA etc etc.
The technicals on this chart RSI and MACD / 20day MA seem to show the selling is not over for TNDM, but a bottom should be put in soon around 58.00 + or - 1% this should technically be followed by a bounce and consolidation into earnings call in late Feb
It seems like we could see a 7-10% + bounce from the $58 low being set in this week to at least $63 and after earnings call in Feb (if all goes as expected from news release and the market is healthy) at a test of the $70 highs by end of March - 20% up in 3 months probably take profits and also a easy stop loss at the level in which the low was set in and near the time stock is bought. If this strategy fails to materialize by middle of jan - bail.
Options actions would be interesting here if you want to play this bounce and earnings call by like March/ April Calls or into the quick money buy calls into the earnings call expiring like mid-Feb. And again could buy an in the money put when you purchase the calls to hedge etc etc etc - if I had more money to play with I would do this like a boss. I do not so I own the stock and will sell if clear lows are not put in by mid next week
TNDM - near channel-topChart is channeling, volume is not strong enough to bring TNDM out of this channel in my opinion. Watch for weakness in this area.
PT ~64
Potential big run soonTNDM could soon follow the rising channel in log-scaled chart. Needs a nice break of box to confirm.
Tandem Diabetes Care Inc Has Huge growth potentialJim Cramer spoke with Kim Blickenstaff, executive chairman at Tandem Diabetes Care (TNDM) , which posted strong earnings last week but quickly reversed, Blickenstaff blamed the sudden reversal in their shares on global uncertainty. He said Tandem has no business in China and is in "acceleration mode."
Currently, only 30% of Type 1 diabetes patients are using a pump, Blickenstaff said, leaving a lot of room for growth for Tandem. The market potential is even greater worldwide, especially in Europe as the condition continues to become a epidemic.
The chart remains bullish but maybe more confirmation required before placing a trade.
TANDEM DIABETES CARE INC.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
AVERAGE ANALYSTS PRICE TARGET $82
AVERAGE ANALYSTS RECOMMENDATION BUY
SHORT INTEREST 7%
